Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chugai R&D Focuses on Low-Molecular-Weight Agonist Antibodies
July 12, 2004
- Policy Promotion HQ Sets Up Coordinators' Group
July 12, 2004
- Takeda, AnGes MG, Sato Sports Join "22nd Century Medical Center" Project
July 12, 2004
- REGULATORY NEWS IN BRIEF
July 12, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 12, 2004
- Annual Financial Results
July 5, 2004
- AstraZeneca May Rank within Top 10 in 2005
July 5, 2004
- Study Design of PROactive of Actos Revealed
July 5, 2004
- 18 Ingredients/25 Products Added to NHI Price List
July 5, 2004
- Micardis Protects Against Early Morning Cardiovascular Events: NBI, Yamanouchi
July 5, 2004
- New Council on Distribution of Ethical Drugs Starts Discussions
July 5, 2004
- Most People Unaware of iNPH: J&J
July 5, 2004
- Korosho Considering Proposal to Reduce Brand Names to Prevent Medical Errors
July 5, 2004
- PRESS SEMINAR
July 5, 2004
- Health Risks Defined in Korosho 2004 White Paper
July 5, 2004
- UPDATE
July 5, 2004
- PFSB Specifies Measures to Prevent Medication Mistakes: Safety Info
July 5, 2004
- BULLETIN
July 5, 2004
- About 36% of the Population Has Allergic Symptoms: Korosho
July 5, 2004
- OTC NEWS IN BRIEF
July 5, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…